CA2061907C - Treatment of ocular hypertension with a synergistic combination - Google Patents

Treatment of ocular hypertension with a synergistic combination Download PDF

Info

Publication number
CA2061907C
CA2061907C CA002061907A CA2061907A CA2061907C CA 2061907 C CA2061907 C CA 2061907C CA 002061907 A CA002061907 A CA 002061907A CA 2061907 A CA2061907 A CA 2061907A CA 2061907 C CA2061907 C CA 2061907C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
keto
component
acceptable salt
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002061907A
Other languages
English (en)
French (fr)
Other versions
CA2061907A1 (en
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of CA2061907A1 publication Critical patent/CA2061907A1/en
Application granted granted Critical
Publication of CA2061907C publication Critical patent/CA2061907C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002061907A 1991-03-01 1992-02-26 Treatment of ocular hypertension with a synergistic combination Expired - Lifetime CA2061907C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6132891 1991-03-01
JP061328/1991 1991-03-01

Publications (2)

Publication Number Publication Date
CA2061907A1 CA2061907A1 (en) 1992-09-02
CA2061907C true CA2061907C (en) 2003-04-08

Family

ID=13167964

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002061907A Expired - Lifetime CA2061907C (en) 1991-03-01 1992-02-26 Treatment of ocular hypertension with a synergistic combination

Country Status (11)

Country Link
US (1) US5547968A (Direct)
EP (1) EP0501678B1 (Direct)
JP (1) JP2511611B2 (Direct)
KR (1) KR100221369B1 (Direct)
AT (1) ATE137407T1 (Direct)
CA (1) CA2061907C (Direct)
DE (1) DE69210286T2 (Direct)
DK (1) DK0501678T3 (Direct)
ES (1) ES2089387T3 (Direct)
GR (1) GR3019820T3 (Direct)
TW (1) TW210287B (Direct)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270349A1 (en) * 1996-11-01 1998-05-14 Jesse A. May Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US7128903B2 (en) * 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242580B1 (en) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
EP0286903B2 (en) * 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
JPH0739343B2 (ja) * 1988-10-01 1995-05-01 株式会社アールテック・ウエノ 眼圧降下剤
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel

Also Published As

Publication number Publication date
JPH0565227A (ja) 1993-03-19
DK0501678T3 (da) 1996-05-28
ATE137407T1 (de) 1996-05-15
EP0501678A2 (en) 1992-09-02
JP2511611B2 (ja) 1996-07-03
DE69210286T2 (de) 1996-09-12
KR920017654A (ko) 1992-10-21
CA2061907A1 (en) 1992-09-02
EP0501678A3 (en) 1992-12-16
KR100221369B1 (ko) 1999-09-15
EP0501678B1 (en) 1996-05-01
ES2089387T3 (es) 1996-10-01
TW210287B (Direct) 1993-08-01
GR3019820T3 (en) 1996-08-31
US5547968A (en) 1996-08-20
DE69210286D1 (de) 1996-06-05

Similar Documents

Publication Publication Date Title
US5432174A (en) Treatment of ocular hypertension
US5212324A (en) Treatment of cataract with 15-keto-prostaglandin compounds
CA2042972C (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
CA2042934C (en) Treatment of ocular hypertension with an ocular synergistic combination
CA2042937C (en) Treatment of ocular hypertension with a synergistic combination
CA2061907C (en) Treatment of ocular hypertension with a synergistic combination
CA2042936C (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
US5405846A (en) Treatment of ocular hypertension with a synergistic combination
US5175189A (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
EP0469782A2 (en) Treatment of cataract with prostacyclin compounds
US5234954A (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
EP0410646B1 (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry